此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Endoscopic vs Non-endoscopic Drainage for Benign Gallbladder Diseases in High-risk Patients or Patients Desiring Gallbladder Preservation (GB-PRESERVE)

2026年6月11日 更新者:Yanglin Pan、Air Force Military Medical University, China

Efficacy and Safety Evaluation of Endoscopic Treatment for Benign Gallbladder Diseases: A Multicenter Prospective Cohort Study

Common gallbladder conditions like gallstones, polyps, and gallbladder inflammation are typically treated by surgically removing the gallbladder. However, surgery may be too risky for elderly patients or those with severe medical conditions, and some patients strongly prefer to keep their gallbladder.

Newer, less-invasive endoscopic treatments can drain the gallbladder to treat inflammation without surgery. However, after successful drainage, doctors currently do not know whether it is better to leave a stent inside for long-term drainage or to actively remove the gallbladder stones using an endoscope.

This multicenter study will follow patients in a real-world setting to compare these two approaches: the endoscopic treatment group (stone removal after drainage) and the non-endoscopic treatment group (long-term drainage alone). The goal is to evaluate which method is safer and more effective over the long term, helping doctors make better clinical decisions and improve patients' quality of life.

研究概览

详细说明

Benign gallbladder diseases, such as symptomatic cholelithiasis, gallbladder polyps, and acute cholecystitis, are common in clinical practice. Although laparoscopic cholecystectomy (LC) remains the gold standard treatment, its application is limited in elderly patients, individuals with severe comorbidities, or specific populations who strongly desire to preserve gallbladder function (termed "high-risk" or specific-preference patients).

In recent years, endoscopic gallbladder drainage techniques characterized by ultra-minimally invasive approaches-such as endoscopic transpapillary gallbladder drainage (ET-GBD) and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD)-have advanced rapidly. These techniques not only provide a critical, life-saving means for patients unable to undergo surgery during the acute phase, but also elevate the therapeutic goal from simple "drainage for inflammation control" to a new height of "long-term disease management" and "organ function preservation." However, following successful drainage, whether to opt for long-term passive drainage via indwelling stents or to actively pursue endoscopic stone removal for a potential "cure" currently lacks guidance from high-level clinical evidence.

Therefore, conducting a large-scale, multicenter, prospective cohort study to evaluate and compare endoscopic treatments for gallbladder diseases holds significant theoretical and practical value. First, at the clinical practice level, this prospective study aims to systematically compare the long-term efficacy and safety between the "endoscopic treatment group" (elective transoral stone removal after drainage) and the "non-endoscopic treatment group" (long-term passive drainage alone). This will provide direct evidence to resolve the core clinical conflict between "gallbladder preservation" and "disease recurrence," driving the treatment paradigm shift from a technical capability-oriented approach to a precise patient benefit-oriented one. Second, at the academic level, this study will be the first to clarify the impact of endoscopic interventions on patients' long-term gallbladder function, quality of life, and subsequent clinical pathways within a large-scale cohort, thereby filling a critical evidence gap in this field. Finally, at the health policy level, the study findings will provide a core foundation for establishing individualized and standardized clinical guidelines, optimizing medical resource allocation, and ultimately improving the overall prognosis and quality of life for patients with complex gallbladder diseases.

研究类型

观察性的

注册 (估计的)

220

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shaanxi
      • Xi'an、Shaanxi、中国、710000
        • Xijing Hospital of Digestive Diseases
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

high-risk acute cholecystitis patients ineligible for surgery, or patients with benign gallbladder diseases who have a strong preference and clinical requirement for gallbladder-preserving therapy

描述

Inclusion Criteria:

  • Age ≥ 18 years, and voluntarily signed the informed consent form;
  • Radiologically confirmed symptomatic benign gallbladder disease (symptomatic gallbladder stones, gallbladder polyps meeting surgical indications, acute cholecystitis TG18 Grade I/II); and meeting any of the following specific population criteria:

    1. High-risk surgical patients: ASA classification ≥ III, or presence of severe comorbidities that significantly increase the risk of laparoscopic cholecystectomy (LC);
    2. Patients with concomitant common bile duct stones (CBDS) and a strong desire for gallbladder preservation: presence of CBDS confirmed by MRCP/ERCP examination, and still strongly requesting the preservation of gallbladder function after being fully informed.

Exclusion Criteria:

  • Suspected or confirmed gallbladder malignancy;
  • Complications requiring emergency surgical intervention (gangrene, perforation, diffuse peritonitis);
  • Uncorrectable severe coagulation dysfunction;
  • Presence of severe anatomical deformity or obstruction of the stomach, duodenum, or esophagus, where the endoscope is expected to be unable to reach the target site (papilla or pericholecystic area);
  • Significant gallbladder atrophy (longitudinal diameter < 4 cm or anteroposterior diameter < 2 cm);
  • Pregnant or lactating women;
  • Previous history of cholecystectomy;
  • Presence of psychiatric disorders or any condition that prevents cooperation with treatment and follow-up;
  • Unwilling or unable to sign the informed consent form.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Endoscopic Treatment Group
Minimally invasive drainage of the gallbladder using endoscopic techniques, which may be followed by elective transoral stone removal.
其他名称:
  • EUS-GBD
  • ET-GBD
Non-endoscopic Treatment Group
Traditional non-endoscopic, percutaneous transhepatic drainage of the gallbladder, typically involving long-term passive drainage.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Overall Adverse Events
大体时间:Up to 1 year after the initial drainage procedure
Adverse events related to the drainage procedure and subsequent treatments, including but not limited to bleeding, infection, bile leak, pancreatitis, and stent-related complications.
Up to 1 year after the initial drainage procedure

次要结果测量

结果测量
措施说明
大体时间
Rate of technical success for EUS-GBD
大体时间:During the procedure
The percentage of participants who achieve successful endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). Technical success is defined as successful placement of a lumen-apposing metal stent (LAMS) in the gallbladder, achieving effective gallbladder drainage via a transmural approach.
During the procedure
Rate of technical success for PT-GBD
大体时间:During the procedure
The percentage of participants who achieve successful percutaneous transhepatic gallbladder drainage (PT-GBD). Technical success is defined as successful placement and establishment of an effective external drainage.
During the procedure
Rate of technical success for ETGBD
大体时间:During the procedure
The percentage of participants who achieve successful endoscopic transpapillary gallbladder drainage (ETGBD). Technical success is defined as successful crossing of the anatomical barriers of the papilla and the cystic duct, and successful placement of an endoscopic nasogallbladder drainage (ENGBD) tube or an endoscopic gallbladder stent (EGBS) within the gallbladder.
During the procedure
Clinical success
大体时间:Within 3 days (72 hours) postoperatively
Clinical success is defined as symptom resolution within 3 days (72 hours) after surgery, characterized by defervescence and improved abdominal pain, along with improvement in inflammatory markers including a white blood cell count of < 10 × 10^9/L and a continuous downward trend in C-reactive protein (CRP) levels synchronous with clinical improvement.
Within 3 days (72 hours) postoperatively
Unplanned re-interventions within 1 year postoperatively
大体时间:At 72 hours, 14 days, 30 days, 90 days, 6 months, and 1 year postoperatively
Through postoperative inpatient observation and post-discharge telephone follow-ups, the investigators will monitor and record whether patients require any additional, unplanned secondary invasive procedures (including endoscopic therapy, interventional radiologic puncture, or surgery) following successful initial gallbladder drainage (such as EUS-GBD, PT-GBD/PTGBD, or ETGBD) or surgical treatment, resulting from unexpected clinical deterioration, drainage device malfunction/failure, or treatment-related complications.
At 72 hours, 14 days, 30 days, 90 days, 6 months, and 1 year postoperatively
Early adverse events
大体时间:14 days postoperatively
14 days postoperatively
Late adverse events
大体时间:30 days, 90 days, 6 months, and 1 year postoperatively
30 days, 90 days, 6 months, and 1 year postoperatively
Change in EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Index Score
大体时间:6 months postoperatively, and 1 year postoperatively
The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L index score ranges from values below 0 (health states worse than death) to 1.0 (perfect health). Higher scores indicate better health-related quality of life.
6 months postoperatively, and 1 year postoperatively
Change in Gastrointestinal Quality of Life Index (GIQLI) Total Score
大体时间:6 months postoperatively, and 1 year postoperatively
The Gastrointestinal Quality of Life Index (GIQLI) is a validated questionnaire assessing gastrointestinal symptoms, physical status, emotional status, social function, and treatment effects. Total scores range from 0 to 144, with higher scores indicating better gastrointestinal quality of life.
6 months postoperatively, and 1 year postoperatively
Total length of hospital stay
大体时间:From date of admission through date of discharge, up to 30 day
From date of admission through date of discharge, up to 30 day
Total cost of hospitalization
大体时间:Through discharge, up to 30 days
Through discharge, up to 30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年5月30日

首先提交符合 QC 标准的

2026年6月11日

首次发布 (实际的)

2026年6月16日

研究记录更新

最后更新发布 (实际的)

2026年6月16日

上次提交的符合 QC 标准的更新

2026年6月11日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅